» Articles » PMID: 25681486

Inflammatory Markers in ST-elevation Acute Myocardial Infarction

Overview
Date 2015 Feb 15
PMID 25681486
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

After acute myocardial infarction, ventricular remodeling is characterized by changes at the molecular, structural, geometrical and functional level that determine progression to heart failure. Inflammation plays a key role in wound healing and scar formation, affecting ventricular remodeling. Several, rather different, components of the inflammatory response were studied as biomarkers in ST-elevation acute myocardial infarction. Widely available and inexpensive tests, such as leukocyte count at admission, as well as more sophisticated immunoassays provide powerful predictors of adverse outcome in patients with ST-elevation acute myocardial infarction. We review the value of inflammatory markers in ST-elevation acute myocardial infarction and their association with ventricular remodeling, heart failure and sudden death. In conclusion, the use of these biomarkers may identify subjects at greater risk of adverse events and perhaps provide an insight into the mechanisms of disease progression.

Citing Articles

The prognostic and therapeutic significance of polyunsaturated fatty acid-derived oxylipins in ST-segment elevation myocardial infarction.

Du Z, Lu Y, Ma Y, Yang Y, Luo W, Liu S Imeta. 2025; 4(1):e266.

PMID: 40027487 PMC: 11865345. DOI: 10.1002/imt2.266.


Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome.

Bulnes J, Gonzalez L, Velasquez L, Orellana M, Munoz Venturelli P, Martinez G Front Cardiovasc Med. 2024; 11:1356023.

PMID: 38993522 PMC: 11236697. DOI: 10.3389/fcvm.2024.1356023.


Predictive value of neutrophil-to-lymphocyte ratio in coronary chronic total occlusion patients.

Li Q, Yu Y, Zhou Y, Zhao Y, Wu J, Wu Y J Geriatr Cardiol. 2024; 21(5):542-549.

PMID: 38948892 PMC: 11211907. DOI: 10.26599/1671-5411.2024.05.007.


Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.

Tavares C, Azevedo L, Rea-Neto A, Campos N, Amendola C, Kozesinski-Nakatani A JAMA. 2024; 332(5):401-411.

PMID: 38873723 PMC: 11304119. DOI: 10.1001/jama.2024.10510.


Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities.

Hilgendorf I, Frantz S, Frangogiannis N Circ Res. 2024; 134(12):1718-1751.

PMID: 38843294 PMC: 11164543. DOI: 10.1161/CIRCRESAHA.124.323658.